A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells

被引：0
|
作者：
Chaux, P
Lethé, B
Van Snick, J
Corthals, J
Schultz, ES
Cambiaso, CL
Boon, T
van der Bruggen, P
机构：
[1] Ludwig Inst Canc Res, B-1200 Brussels, Belgium
[2] Univ Louvain, Cellular Genet Unit, Brussels, Belgium
[3] Free Univ Brussels, Sch Med, Physiol Lab, B-1000 Brussels, Belgium
[4] Univ Louvain, Expt Med Unit, Brussels, Belgium
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2001年 / 31卷 / 06期
关键词：
MAGE; CD4(+); dendritic cell; tumor immunity; antigen; peptide; epitope;
D O I：
10.1002/1521-4141(200106)31:6<1910::AID-IMMU1910>3.0.CO;2-K
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Antigens encoded by MAGE genes and recognized by T cells are of interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Several MAGE-1 peptide that are recognized by CD8(+) cytolytic T lymphocytes have been used in therapeutic vaccination trials. To obtain anti-tumor immune response, vaccines combining peptides recognized by CD8(+) and peptides recognized by CD4(+) T cells might be optimal. We focused therefore on the identification of MAGE peptides recognized by CD4(+) T cells. We report here the identification of MAGE-1 epitope EYVIKVSARVRF, which is presented to CD4+ T lymphocytes by HLA-DR15. This HLA allele is present in 29% of Asians and 17% of Caucasians.
引用
收藏
页码：1910 / 1916
页数：7
相关论文
共 50 条
  • [1] A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells
    Sabrina Ottaviani
    Yi Zhang
    Thierry Boon
    Pierre van der Bruggen
    Cancer Immunology, Immunotherapy, 2005, 54 : 1214 - 1220
  • [2] A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells
    Ottaviani, S
    Zhang, Y
    Boon, T
    Van der Bruggen, P
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (12) : 1214 - 1220
  • [3] A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes
    Schultz, ES
    Lethé, B
    Cambiaso, CL
    Van Snick, J
    Chaux, P
    Corthals, J
    Heirman, C
    Thielemans, K
    Boon, T
    van der Bruggen, P
    CANCER RESEARCH, 2000, 60 (22) : 6272 - 6275
  • [4] Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors
    Corbière, V
    Nicolay, H
    Russo, V
    Stroobant, V
    Brichard, V
    Boon, T
    van der Bruggen, P
    TISSUE ANTIGENS, 2004, 63 (05): : 453 - 457
  • [5] A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz, ES
    Schuler-Thurner, B
    Lethé, B
    Cambiaso, CL
    Van Snick, J
    Chaux, P
    Corthals, J
    Heirman, C
    Thielemans, K
    Boon, T
    van der Bruggen, P
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (06) : 1170 - 1170
  • [6] A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein
    Zhang, Y
    Chaux, P
    Stroobant, V
    Eggermont, AMM
    Corthals, J
    Maillère, B
    Thielemans, K
    Marchand, M
    Boon, T
    van der Bruggen, P
    JOURNAL OF IMMUNOLOGY, 2003, 171 (01): : 219 - 225
  • [7] MAGE-6 encodes HLA-DRβ1*0401-presented Epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
    Tatsumi, T
    Kierstead, LS
    Ranieri, E
    Gesualdo, L
    Schena, FP
    Finke, JH
    Bukowski, RM
    Brusic, V
    Sidney, J
    Sette, A
    Logan, TF
    Kasamon, YL
    Slingluff, CL
    Kirkwood, JM
    Storkus, WJ
    CLINICAL CANCER RESEARCH, 2003, 9 (03) : 947 - 954
  • [8] A MAGE-A3 peptide presented by HLA-DP4 tumor cells to CD4+ cytolytic T lymphocytes
    Schultz, ES
    Lethé, B
    Van Snick, J
    Chaux, P
    Thielemans, K
    Corthals, J
    Heirman, C
    Boon, T
    van der Bruggen, P
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 563 - 563
  • [9] New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells
    Kobayashi, T
    Lonchay, C
    Colau, D
    Demotte, N
    Boon, T
    van der Bruggen, P
    TISSUE ANTIGENS, 2003, 62 (05): : 426 - 432
  • [10] An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
    Ayyoub, M
    Hesdorffer, CS
    Montes, M
    Merlo, A
    Speiser, D
    Rimoldi, D
    Cerottini, JC
    Ritter, G
    Scanlan, M
    Old, LJ
    Valmori, D
    JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (08): : 1225 - 1233
12345